

1 Dalmore Drive,  
Scoresby,  
Victoria 3179  
AUSTRALIA  
T: +61 (0)3 9763-1287  
F: +61 (0)3 9763-2817  
[www.generabiosystems.com](http://www.generabiosystems.com)

**Friday 12 April 2019**

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)  
GENERA – KEY EXECUTIVE APPOINTMENT & CAPITAL RAISING UPDATE**

---

Genera Biosystems Limited (ASX:GBI) ('Genera' or 'the Company') is pleased to announce that it has appointed Dr Guillermo Elias Ph.D. to its Executive Leadership Team in the role of Corporate Development Director – North America.

Like Genera's most recent additions of Dr Damian Pethica and Mr Seong Chen to the Executive Leadership Team (refer ASX release 31 August 2018), Dr Elias has a background in areas relevant to Genera's commercialisation strategy, specifically in diagnostics, drug development, commercialisation and launch in the field of precision medicine. Chairman, Lou Panaccio commented, we are delighted to secure the services of Guillermo to complement Seong and Damian who joined the Genera team last September. He will provide invaluable support to CEO, Richard Hannebery in helping drive additional high value partnering deals to further build on the Beckman Coulter Distribution Agreement. In addition to the oncology space Guillermo has tremendous experience in the respiratory field as well as on-the-ground experience in several market jurisdictions that Genera has specific interest in.

Genera CEO, Richard Hannebery added, "Great underlying Tech and great people attract outstanding candidates. The addition of Guillermo, who will be based in the Bay Area of San Francisco, will provide invaluable support and skills on the ground Stateside. Guillermo's exceptional leadership background with Genentech and Roche Diagnostics as well as his start-up experience earlier in his career at iPierian Inc., will undoubtedly complement the skills that exist within our team. With Guillermo's addition we are well positioned to execute our push into the companion diagnostic testing space and progress our well-considered pathway toward a successful licensing of PapType® in the North American market."

**Guillermo Elias, Ph.D. : Director Corporate Development – North America**

Guillermo M. Elias, Ph.D. started at iPierian Inc., in 2008 as Manager of Business Development. He was a member of the start-up team reporting directly to the CEO and helped build the company from incubator phase at USCF to Series C financing. Located in the Bay Area of San Francisco up to and including its Series C financing round iPierian raised US\$77M in venture funding (Kleiner Perkins and MPM Capital) and was acquired by Bristol Myers Squibb in 2014 for US\$725M.

After iPierian Guillermo worked in strategic marketing for a Next Generation Sequencing (NGS) company before joining Roche Diagnostics in 2012 being accepted into their accelerated executive development program. In this program he worked within 4 key areas of the Roche Dx business. These areas included Business Development & Corporate Strategy with the CEO Program Office, Basel Switzerland; International Product manager, Global Marketing, Switzerland and Germany; Sales and Marketing manager Point-of-Care Dx, Latin America Region, Sao Paulo Brazil; and finally,

Product Manager and member of the commercial launch team in Oncology BU at Genentech in South San Francisco.

Following completion of the program Guillermo accepted a position at Genentech as Senior Product manager, Respiratory and Ophthalmology pipeline, Marketing and Launch planning. In this role he led cross functional USA/Genentech and Global/Roche teams to develop innovative go-to-market launch strategies based on Companion Diagnostics (CDx).

At Genentech he led the development and launch of the Genentech Respiratory Franchise brand marketing campaign – Pulmozyme™, Esbriet™ and Xolair™ and cross-functional partners (med affairs, sales leadership/field personnel, market access, public relations, regulatory, legal, compliance, market planning, competitive intelligence) and external agencies to define commercial strategies and tactics based on rigorous, multifaceted market research; developed branding, positioning, personality and messaging.

He most recently worked as Director of Business Development at Corvus Pharmaceuticals where he directed all aspects of corporate partnering negotiations for a Phase 1b/2 immune-oncology asset. At Corvus he directed deal flow process and supported the CEO and CBO in direct negotiations; directed the corporate roadshow at the JP Morgan Healthcare Conference 2018 including development of presentations and organization of non-confidential meetings, confidential strategic partnering negotiations, and CEO-to-CEO level meetings with top-5 oncology pharma companies.

Having extensive experience presenting at Board level, Guillermo has well developed skills and experience in market analytics, financial modelling and legal/contracting strategy to substantiate business cases and evaluate strategic partnering options.

Guillermo holds a BA in Biological Sciences Rutgers University (Departmental Magna Cum Laude; Dean's List). He holds a Ph.D. Neuroscience, Herbert Boyer Program in Biological Sciences, University of California, San Francisco (UCSF).

### **Capital Raising Update**

On 20 March Genera closed its 4 for 5 non-renounceable entitlements issue at an Issue Price of \$0.13 per new share (the “**Entitlements Issue**”). Upon close the Entitlements Issue did not meet the Minimum Subscription level to facilitate the allotment of new shares. Genera is working toward the goal of placing the required amount of shortfall shares by 30 April in order to meet the Minimum Subscription. Should the Minimum Subscription not be met by 30 April all application monies received under the Entitlements Issue shall be returned to applicants without interest.

Up until 3 months post the Closing Date of Entitlements Issue (20 June 2019) the Board of Genera at its sole discretion may place any available shortfall shares to investors. The application of proceeds of the Entitlements Issue and any subsequent shortfall placement are set out Genera's prospectus. A significant amount of funds planned to be raised under the prospectus are to be applied to the redemption of existing Series B Convertible Notes (the “Notes”).

Under the terms of the Notes no security is enforceable without 75% of all Notes by value electing in writing to proceed to enforcement. Genera will continue to act collegiately with Noteholders in the provision of a mutually acceptable pathway to deliver a redemption of the outstanding Series B Notes.

**Lodgement of 31 December Half Year 2019 Accounts**

Genera is on track to lodge its accounts for the 6 months to 31 December 2018 within the next 10 Business Days.

---

For further information please contact:

Mr Richard Hannebery  
Chief Executive Officer  
Genera Biosystems Limited  
Telephone: +61 (0)3 9763 1287  
[www.generabiosystems.com.au](http://www.generabiosystems.com.au)

**About Genera Biosystems** : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.<sup>1</sup>

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2<sup>nd</sup> half of 2018, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’).

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

---

<sup>1</sup> All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.